Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BN.4SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
CK.1.4SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BQ.1.1.11SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BA.4.6.4SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BQ.1.3SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BQ.1.5SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BA.2.75.5SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BF.7.8SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BQ.1.1.40SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
DM.1SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BQ.1.1.60SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BQ.1.1.49SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
CK.2.1SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BQ.1.13SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
JN.1.9.2SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
XDK.2SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
XBB.1.16.16SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
KT.1.2SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-613.77China
LE.2SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
JN.1.7.7SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-17784.4China
JN.1.49.2SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-27219.1China
BQ.1.1.60NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26313.4US
BQ.1.1.49NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CK.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26313.4US
JN.1.9.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDK.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KT.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LE.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.7.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAGNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.9.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.4.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DJ.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.69NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.98NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
XBB.1.5.71NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HT.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.90NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
FB.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.18.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used